1:03 PM
 | 
Jul 06, 2018
 |  BioCentury  |  Emerging Company Profile

Tethering bleeding risk

Tetherex’s antithrombotic therapy could reduce or eliminate risks of bleeding

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding.

Chairman and CEO Scott Rollins said while antithrombotic drugs including generic heparin, warfarin and approved Factor Xa inhibitors “do a good job of stopping thrombosis,” they carry risks of bleeding because they block the coagulation system. There are nine marketed VTE drugs, according to BioCentury’s BCIQ database, and all of them carry warnings on their label for bleeding or caution against use in patients at risk for hemorrhage.

SelK2 avoids blocking the coagulation cascade, which Rollins said gives it the “potential to be the first drug to block thrombosis without causing bleeding at the same time.”

Tetherex spun out of Selexys Pharmaceuticals Corp. in 2014 to continue work on...

Read the full 662 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >